Posted on Leave a comment

Why the World’s Highest Virus Death Rate Is in Europe’s Capital

In an art-deco building in the heart of Brussels, Belgium’s leading scientists gather daily to announce the country’s coronavirus toll. It’s been grim reading.

Despite having only 11 million people, the country has reported more deaths from the disease than China. With some 57 fatalities per 100,000 inhabitants, it has the highest per-capita death rate in the world — almost four times that of the U.S.

Share this

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp
Share on email

Belgian Toll

Europe’s highest coronavirus death rates are in tiny Belgium

 

Source: ECDC, data as of April 24

According to Belgian officials, the reason for the grisly figures isn’t overwhelmed hospitals — 43% of intensive-care beds were vacant even at the peak of the crisis — but the country’s bureaucratic rigor.

Unlike many other countries, the home of the European Union’s top institutions counts deaths at nursing homes even if there wasn’t a confirmed infection.

“We often get criticism — oh, you’re making Belgium look bad — we think it’s the opposite,” Steven Van Gucht, head of the viral disease division at the Sciensano public-health institute, said while maintaining the requisite distance of 1.5 meters (5 feet). “If you want to compare our numbers with a lot of other countries, you basically have to cut them in half.”

Clearer Picture

About 95% of Covid-19 deaths in elderly care homes haven’t been diagnosed, yet Belgium makes the decision to register them based on the symptoms shown and who the people have been in contact with. The goal is to get a clearer picture of the outbreak and better target hot spots.

At the start of each briefing at the Residence Palais, a stone’s throw from the European Commission, Belgian officials detail the day’s statistics in French and Dutch. They draw particular attention to those who die outside of hospitals — typically around half the total.

The impact of the disease on vulnerable care-home residents is a growing issue. While Europe knew it would need more ventilators and intensive-care capacity once the virus spread beyond China, the impact on nursing homes was unexpected, according to Agoritsa Baka, a senior expert at the European Centre for Disease Prevention and Control.

“It’s a disaster,” she said. “We did not realize how devastating Covid would be if it entered these populations.”

Excess Mortality

Yet not all European countries are measuring the impact in the same way, meaning that the numbers of coronavirus deaths are likely thousands higher than the official count of more than 110,000.

The consequence of uneven practices was evident in France. When the country reported data from some nursing homes for the first time in early April, those fatalities were almost double the number of people that died in hospitals.

Last week, Spain had to adjust its historical data after Catalonia started including people who had symptoms but didn’t test positive. This week a local radio broadcaster reported that more than 6,800 elderly died in Spanish nursing homes with symptoms but weren’t recorded in official data.

Germany’s unusually low mortality rate may be helped by the fact that the country only counts deaths that have a positive virus test.

Such discrepancies show up in a concept called “excess mortality,” the number of extra fatalities above typical trends. In Belgium, just over 300 people normally die every day, but this year, it’s jumped to nearly 600.

A project called euroMOMO, originally developed for gauging the scale of flu epidemics, is now being used to track the impact of the coronavirus in Europe.

Good Surveillance

Belgium’s practice means that nearly all deaths are accounted for in a given week, while neighboring Netherlands has around 1,000 undefined fatalities. Some countries’ virus deaths are around a sixth of their excess mortality rates.

Better tracking could help improve Europe’s response to outbreaks, especially as the region gradually eases lockdown restrictions, raising the prospect of second-wave outbreaks. Coordinated procedures could also defuse tensions as Europe grapples with recovery efforts.

“We are still in a situation where within the EU we do not count the same way, which could lead to political misunderstandings,” said Pascal Canfin, chair of EU Parliament’s environment and health committee. “It leads to different perception awareness of the crisis.”

In the meantime, the world’s eyes shouldn’t be focused on Belgium because at least the extent of the problem is known, according to Van Gucht.

“When you have a good surveillance system, you report a lot of cases,” he said. “It’s the countries that are not reporting or that are reporting very low numbers, you should be more worried about.”

HOW D’OXYVA CAN HELP?

D’OXYVA is the only fully noninvasive, completely painless over-the-skin microcirculatory and nerve stimulant solution that has been validated to significantly improve microcirculation.

The improvement of microcirculation, i.e., blood flow to the smallest blood vessels, benefits one’s health, immune system and overall sense of well-being in a variety of ways.

Our organization has been on the forefront in the fight against the novel coronavirus that originated in Wuhan, China (Covid-19) since January of this year due to our organization’s operations in major countries across Asia. We all should understand the need to act now and arrest this crisis head on by spurring economic activity wherever we can and providing effective, affordable and rapid testing and treatments for the masses.

Reduce unwanted doctor visits, recommended and ranked top by experts!

Posted on Leave a comment

New COVID-19 Clinical Trial Announced To Treat Over 90% of Patients With Underlying Medical Conditions

A new clinical trial is being announced today that could significantly increase the rate of recovery for COVID-19 patients with underlying health conditions and save lives! Circularity Healthcare’s trial will help some of the most at-risk patients suffering from complications due to diabetes, poor circulation, hypertension, cardiovascular disease and high blood pressure. The trial will involve the use of Circularity’s already FDA-approved drug and IDE device D’OXYVA® (deoxyhemoglobin vasodilator) – a non-toxic, non-invasive microcirculation transdermal device.  It is the first biotech solution of its kind to improve overall oxygen-rich blood flow. The device has been shown to significantly heal diabetic wounds, reduce the risks of amputations, prevent sepsis and septic shock,  improve blood pressure and general vital organ function of the pancreas, liver, brain and kidneys, while increasing overall health for some of the most vulnerable patients. 

Share this

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp
Share on email

“Anyone who suffers from an underlying condition should know that this proven treatment option is available,” says Circularity Healthcare CEO Norbert Kiss. “Every medical report released so far shows that severe COVID-19 patients need blood oxygenation and blood thinners. The overwhelming majority of patients have diabetes and cardiovascular issues beyond pulmonary complications and they all have sepsis setting in early on. These are the exact main vitals and chronic diseases D’OXYVA improves like no other medication currently available on the market.”

The recommendation for this new treatment is based on the following:

  • After eight years of three dozen human studies with leading experts at some of the most prestigious universities and hospitals in the world (including Penn State and Airlangga University), zero adverse effects were reported. D’OXYVA is currently expanding its Phase 3 trial with Professor David G. Armstrong and his colleagues.
  • The pharmaceutical-grade CO2 utilized by the D’OXYVA device has already been approved by the FDA (it is the same CO2 drug already readily available in every hospital and provided by the same supplier). There is just a 1-2 week IRB approval to launch the trials at any location due to the investigational device exemption (IDE) status of D’OXYVA. Additionally, with the device factory S.-based in Fremont, CA, all the regulated products are also readily-available to launch the trial.
  • The effects of transdermal CO2 have been widely noted in wound care as demonstrated in clinical studies. Healing, closure, prevention against sepsis and septic shock and recovery of an ulcer (non-healing) due to diabetes and cardiovascular complications are much faster and often successful where other modalities have failed.
  • All research projects performed up to date have consistently recorded a significant decrease in systolic blood pressure (from the heart) and diastolic (return to the heart) blood pressure. These results have been consistent throughout all study time periods   up to 240 minutes (the longest time period evaluated after treatment).
  • Systemically, CO2 therapy has shown great success to improve the healthcare of patients with high blood pressure, general vital organ function of patients with high blood pressure, and general vital organ function like that of the pancreas, liver, brain, and kidneys

The clinical trials are now waiting IRB approvals and are about to launch under existing contracts at multiple sites including top U.S. universities such as Harvard, Yale, M.I.T, USC, and UCLA, with more physicians and patients being invited to participate. Since the product can be monitored at home, potential patients do not have to be currently admitted to a hospital in order to take part in the trial. For more information on the trial or to sign up, please visit https://doxyva.com/covid-19/ or call 626.240.0956.

About Circularity Healthcare, LLC
Circularity Healthcare, LLC, located in Los Angeles, CA, is a private biotech and MedTech products and services company that designs, makes, markets, sells, distributes, and licenses its patented and patent-pending technologies, such as its flagship non-invasive deoxyhemoglobin vasodilator product line, D’OXYVA®. One of the main mechanisms underlying D’OXYVA’s science received the Nobel Prize for Medicine in 2019. Circularity enters into exclusive agreements with manufacturers to launch products in large and small clinics and hospitals to help enhance their profits and credit profiles with a wide variety of advanced products and services. In addition, Circularity Healthcare assists in the financing of equipment, working capital, and patient financing at industry-leading terms and speed.

For more information, please visit http://www.circularityhealthcare.com or http://doxyva.com; doctors (Rx only) visit http://wound.doxyva.com and send your general inquiries via the Contact Us page. For specific inquiries, contact Circularity Customer Care at info(at)doxyva(dot)com, info(at)circularityhealthcare(dot)com, or by phone (toll free) at 1-855-5DOXYVA or 1-626-240-0956.

Forward-Looking Information
This press release may contain forward-looking information. This includes, or may be based upon, estimates, forecasts and statements as to management’s expectations with respect to, among other things, the quality of the products of Circularity Healthcare, LLC, its resources, progress in development, demand, and market outlook for non-invasive transdermal delivery medical devices. Forward-looking information is based on the opinions and estimates of management at the date the information is given and is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those initially projected. These factors include the inherent risks involved in the launch of a new medical device, innovation and market acceptance uncertainties, fluctuating components and other advanced material prices, new federal or state governmental regulations, the possibility of project cost overruns or unanticipated costs and expenses, uncertainties relating to the availability and costs of financing needed in the future and other factors. The forward-looking information contained herein is given as of the date hereof and Circularity Healthcare, LLC assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law. Circularity Healthcare, LLC makes no representations or warranties as to the accuracy or completeness of this press release and shall have no liability for any representations (expressed or implied) for any statement made herein, or for any omission from this press release.

Reduce unwanted doctor visits, recommended and ranked top by experts!